Reeds Stock News

Reeds (REED) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Reed's, Inc. (REED) Q4 2023 Earnings Call Transcript

NORWALK, Conn., March 19, 2024 (GLOBE NEWSWIRE) -- Reed's, Inc. (OTCQX: REED) (“Reed's” or the “Company”), owner of the nation's leading portfolio of handcrafted, natural ginger beverages, wil

NORWALK, Conn., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Reed's, Inc. (OTCQX: REED) (“Reed's” or the “Company”), owner of the nation's leading portfolio of handcrafted, natural ginger beverages, will

Reed's, Inc. (OTCQX:REED) Q2 2023 Earnings Conference Call August 10, 2023 5:00 PM ET Company Participants Norman Snyder - CEO Joann Tinnelly - Interim CFO Conference Call Participants Sean McGowan -

Reeds (REED) came out with a quarterly loss of $0.99 per share versus the Zacks Consensus Estimate of a loss of $1.32. This compares to loss of $2.50 per share a year ago.

Reeds (REED) came out with a quarterly loss of $1.70 per share versus the Zacks Consensus Estimate of a loss of $1.02. This compares to loss of $2.50 per share a year ago.

NORWALK, Conn., May 22, 2023 (GLOBE NEWSWIRE) -- Reed's, Inc. (OTCQX: REED) (“Reed's” or the “Company”), owner of the nation's leading portfolio of handcrafted, natural ginger beverages, will

Reed's, Inc. (OTCQX:REED) Q4 2022 Earnings Conference Call March 29, 2023 5:00 PM ET Company Participants Norman Snyder - Chief Executive Officer Thomas Spisak - Chief Financial Officer Conference Cal

Reeds (REED) delivered earnings and revenue surprises of -94.53% and 0.40%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Reeds (REED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Gainers Sera Prognostics, Inc. (NASDAQ: SERA) shares surged 63.4% to $2.11 after the company announced top-line data from the AVERT PRETERM TRIAL. TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares c

The Company Anticipates Trading to Begin on the OTCQX on Thursday, February 16 The Company Anticipates Trading to Begin on the OTCQX on Thursday, February 16

Friday, January 27, 2023 Friday, January 27, 2023

Gainers Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) shares surged 85% to $2.2200. Sonoma Pharmaceuticals and EMC Pharma announced Department of Defense DAPA registration for Microcyn(R) Rx products.